A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Trial Profile

A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications CNS cancer; Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Toxicity results of ibrutinib in combination with high-dose methotrexate (HD-MTX) in r/r PCNSL/SCNSL (n=6) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results (n=25) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 22 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top